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This study was carried out to estimate the direct and indirect costs associated with asthma and chronic obstructive
pulmonary disease (COPD) in Sweden in 1980 and 1991, and to identify trends in the use of outpatient care, drugs
and inpatient care, and the development of temporary morbidity, permanent disability and mortality for asthma
and COPD.
Routinely published administrative and population data were used to estimate the costs of asthma and COPD,
and these figures were compared to corresponding estimates and trends for all respiratory diseases as well as for all
diseases.
Asthma and COPD each accounted for about SEK 3 billion, together roughly 2% of the economic cost of all
diseases. Although the total costs associated with each disease were similar, the distribution of the dierent cost
components and changes in each component over time diered. During the 1980s, the cost of drugs and out-patient
care increased for both diseases. The cost of inpatient care for asthma decreased, whereas that for COPD increased.
This study shows that asthma therapy has changed from inpatient to ambulatory care in Sweden, while the
treatment of COPD to a higher degree still is based on inpatient care.
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Health economics has become accepted as an important
aspect of modern medicine, as it provides useful informa-
tion on the costs to society associated with particular
diseases and the cost-eectiveness of dierent treatment
options. These considerations are particularly important in
relation to common and chronic conditions such as asthma
and chronic obstructive pulmonary disease (COPD).
The total cost associated with illness comprises direct
costs, indirect costs and intangibles (1–3). Direct costs are
those associated with the prevention, diagnosis and
treatment of the disease, while indirect costs are those
arising from a reduced working capacity among the
patients. Intangible costs arise from patients’ pain, suering
and decreased quality of life; these are seldom reported,
partly because they are dicult to measure and partly
because there are dierent opinions regarding how to value
reductions in quality of life. Nevertheless, direct andReceived 8 June 1999 and accepted 26 October 1999.
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nity Medicine, S - 205 02 Malmo¨, Sweden, Fax: +46 40 33 62 15.
0954-6111/00/030247+09 $35?00/0indirect costs provide a reasonable estimate of the economic
impact of disease.
Asthma and COPD are important diseases from a public
health point of view, since they reduce the well-being of a
substantial and increasing share of the population. In
Sweden, studies report on increased asthma and COPD
prevalences (4–7), with a higher asthma prevalence in
women (6,8,9). Studies from the United States show that
asthma mortality has increased since the late 1960s (10–13),
whereas in Sweden mortality from asthma has been
relatively stable since the 1950s, while COPD mortality
has increased (14). Moreover, the treatment of asthma has
changed during the last decade. The recognition that
asthma is an inflammatory disease (15–18) has led to the
introduction of new anti-inflammatory drugs, primarily
inhaled corticosteroids. This development has markedly
influenced the economic costs associated with asthma (19).
Similarly, the most important risk factor for COPD is
smoking, and smoking patterns have changed substantially
in developed countries in recent years. In Sweden, for
example, the proportion of male smokers decreased in all
age groups between 1980–1981 and 1988–1989 (20). In
women, the proportion of smokers increased in those aged
45–84 years but decreased in women aged 16–44 years.# 2000 HARCOURT PUBLISHERS LTD
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impact of asthma and COPD must also have changed
substantially.
The objectives of this study were to estimate the direct
and indirect costs of asthma and COPD in Sweden 1980
and 1991, and to identify trends in the use of healthcare
resources and the development of temporary morbidity,
permanent disability and mortality related to asthma and
COPD. In addition, estimated costs for asthma and COPD
were related to corresponding estimates for all respiratory
diseases and for all diseases.
BACKGROUND: THE SWEDISH
HEALTHCARE SYSTEM
The economic costs associated with a disease are not only
determined by the prevalence of the disease, but are also
influenced by factors such as the organization and finance
of healthcare, the regulation of social insurance, the general
standard of living, etc. In Sweden, healthcare provision and
funding is primarily public. The main political responsi-
bility for healthcare rests with 26 county councils, but in
1992 the responsibility for long-term care for the elderly
and disabled was taken over by the 278 local municipalities.
Both county councils and local municipalities are empow-
ered to impose proportional income taxes on their citizens
(21,22).
In 1991, total sales of drugs amounted to SEK 108
billion, of which 72% was subsidised by the state. Drugs
used in treating certain chronic illnesses were supplied free
of charge to the patient; drugs prescribed for asthma
belonged to this group, while those prescribed for COPD
did not during the study period. This means that there was
an incentive for the physician (and the patient) to report the
diagnosis as asthma rather than COPD, since the same
drugs could be used to treat the inflammatory component
of the two diseases.
In 1980, no compensation was paid for loss of earnings
during the first day of sickness, whereas in 1991 compensa-
tion was payable from the first day of illness. Furthermore,
the criteria for eligibility to receive sickness benefit were
changed several times between 1980 and 1991. In 1980,
working capacity had to be reduced by at least a half of
what was considered normal for a person to be eligible for
benefit, whereas by 1991 this threshold had been decreased
to at least one quarter of normal. This is an important
consideration because in illnesses such as asthma and
COPD, a person may continue to work despite feeling ill
and having a reduced working capacity; the decision to
continue working is likely to depend largely on the
compensation rules (23).
Material and methods
In this study, asthma was defined as code 493 (International
Classification of Diseases, Ninth Revision) whereas COPD
included codes 490 (bronchitis UNS), 491 (chronic bron-
chitis), 492 (emphysema) and 496 (chronic airway obstruc-tion not elsewhere classified); code 494 (bronchiectasis) was
included for data on inpatient care, outpatient care, drug
costs and permanent disability; code 519w (respiratory
insuciency) with a second diagnosis of COPD was
included for data on inpatient care.
Data on outpatient care, general practitioner (GP) visits
and prescribed drugs by disease were obtained from a
sample of one sixteenth of all physicians (24). Data were
collected twice a year and included all consultations made
to the physician during a 7-day period. These data were
then extrapolated to the entire population. Information on
the duration of inpatient care (bed-days by disease) was
reported by the National Board of Health and Welfare (25).
Estimates of cost per bed-day (for each speciality) and per
physician visit, published annually by the Federation of
County Councils for a selection of the Swedish hospitals
(26), were used to obtain the total cost of inpatient care,
outpatient care and GP visits for each disease. The state
monopoly retailer of drugs supplied data on the costs of
pharmaceuticals (27).
Data on age-, gender- and disease-specific mortality were
obtained from the Swedish Central Board of Statistics (14),
and data on the number of persons granted early retirement
pension, according to age, gender and cause, were obtained
from the Swedish National Board of Social Insurance (28).
These two sets of data were used to calculate the number of
productive life-years lost through asthma or COPD.
Age- and gender-specific estimates of average earnings
for full-time workers in 1991 (29,30), including employers’
contribution to social insurance; i.e. an additional 40% on
earnings, were used to estimate the value of lost production.
When the present value of future earnings was calculated, a
discount rate of 5% was used. The indirect costs in 1980,
reported in 1991 prices, were calculated from the annual
incomes in 1991, adjusted for the increase in overall
productivity between 1980 and 1991 (31). When estimating
the cost of permanent disability, we took account of the fact
that persons receiving early retirement pensions have a
shorter expected lifespan than the population at large (32).
Two studies reporting diagnosis-related absence from
work due to illness in 1983 and 1990 (33,34) were used to
estimate the disease-specific number of productive days lost
due to temporary morbidity. It should be observed that
these studies used very small samples (roughly 2 and 04%,
respectively, of all reported spells of absence due to
sickness). In addition, the validity of the diagnoses is not
perfect; either individuals reported their diagnoses them-
selves, or the diagnoses were set by a physician early in the
course of the illness and, hence, with some degree of
uncertainty. Diagnosis-related data on parents staying




Table 1 summarizes the economic cost associated with
asthma and COPD in 1980 and 1991, and compares these
TABLE 1. The economic cost associated with asthma and COPD (million SEK), and costs associated with all illnesses and diseases of the respiratory system (billion SEK), in
Sweden in 1980 and 1991 (all costs are expressed in 1991 prices)
Diseases of the
Asthma COPD All illnesses* respiratory system*
1980 1991 1980 1991 1980 1991 1980 1991
million million million million billion billion billion billion
SEK % SEK % SEK % SEK % SEK SEK SEK SEK
Direct costs 789 (36) 1114 (37) 699 (35) 1085 (39) 874 1044 56 81
Pharmaceuticals 89 336 78 137 67 108 07 16
Outpatient care etc. 227 472 281 434 207 281 22 30
Inpatient care 473 306 340 514 600 655 28 35
Indirect costs 1420 (64) 1907 (63) 1322 (65) 1699 (61) 1377 1654 146 141
Temp. morbidity 328 866 519 926 601 729 119 116
Perm. disability 782 864 587 578 479 632 16 16
Mortality 310 177 216 195 296 293 11 09
Total costs 2209 (100) 3021 (100) 2021 (100) 2784 (100) 2250 2698 201 221




































250 L. JACOBSON ET AL.with the economic costs of all illnesses and all respiratory
system diseases. The direct costs associated with respiratory
diseases accounted for approximately 8% of the direct costs
of all diseases in 1991; among all main disease categories
according to the International Classification of Diseases,
only mental disorders and diseases of the circulatory system
accounted for a greater proportion of the direct cost (18%
and 17%, respectively) (3). Between 1980 and 1991, asthma
and COPD increased their share of the economic costs of
respiratory diseases from 21% to 26% and their share of
the economic costs of all illnesses from 1.9 to 2.2%.
Figure 1 shows the change in each cost component for
the two diseases between 1980 and 1991. For asthma, costs
associated with drugs and outpatient care increased to a
similar extent during this period, whereas costs resulting
from inpatient care and mortality decreased. For COPD,
the cost of inpatient care increased more than drug costs,
and there were slight decreases in costs resulting from
permanent disability and mortality.
DIRECT COSTS
The total number of consultations (outpatient care and GP
visits), reported as the average number over three
consecutive years, increased from 274 000 in 1981 to
496 000 in 1991 for asthma; the corresponding figures for
COPD were 327 000 and 491 000, respectively. Together,
asthma and COPD accounted for about 4% of all
consultations in the early 1990s, whereas at the beginning
of the 1980s asthma accounted for about 12% and COPD
for about 17%. In 1991, 45% of consultations due to
asthma were in the outpatient setting, and these accounted
for 62% of the cost (hospital-based outpatient care
consultations were more expensive than GP consultations).
Outpatient care accounted for 32% of consultations for
COPD, and 47% of the cost.
Figure 2 shows the number of hospital discharges per
100 000 inhabitants for asthma and COPD between 1977
and 1991. In 1980, women accounted for about 30% of theFIG. 1. Changes in the cost of drugs, outpatient care,
permanent disability and mortality for asthma (&) and
COPD (&) between 1980 and 1991 (million SEK, 1991
prices).discharges due to COPD, and this figure had increased to
45% by 1991. Similarly, women accounted for 49% of the
discharges due to asthma in 1980 and 53% in 1991.
Discharges due to COPD or asthma in patients of dierent
ages are shown in Figs 3 and 4, respectively. There was a
slight increase in discharges for COPD among infants (age
0–4 years) between 1980 and 1991, and more marked
increases in patients aged 60–64 years and older. Discharges
for asthma increased among infants and elderly patients
(age about 80 years and above); in all other age groups,
discharge rates tended to decrease between 1980 and 1991.
A similar increase in hospitalization for asthma among
infants is also found in the United States (12,35).
The mean duration of hospital stay (excluding long-term
care) decreased for both diseases between 1980 and 1991.
For the youngest age group (0–9 years), the mean duration
was reduced from 3 days in 1980 to 2–25 days in 1991. For
the oldest age group (age 80 years and above), the mean
duration decreased during the same period from about 15
days to 10 days for COPD, and from 10 days to 8 days for
asthma.
INDIRECT COSTS
The number of individuals granted early retirement
pensions due to asthma was 89/100 000/year in 1980 and
88/100 000/year in 1991–1992. The number of persons
granted early retirement pensions due to COPD decreased
from 123/100 000/year to 80/100 000/year among men,
and increased from 45/100 000/year to 54/100 000/year
among women. For asthma, there was no change in the sex
distribution; men accounted for slightly more than 50% of
the newly granted pensions in 1980 and 1991. By contrast,
there appeared to be an increase in the incidence of new
pensions granted for COPD among women during this
period; women accounted for 30% of newly granted
pensions in 1978, compared with 42% in 1992. Among
persons granted early retirement pension due to COPD in
1991, 10% were younger than 50 years of age and 50%
were aged 60–64 years. The corresponding figures for
asthma were 20% and 40%, respectively.
The estimate of indirect costs arising from mortality
included only individuals who died before the age of 65
years (the legal retirement age in Sweden). In 1991, 97 men
and 58 women below this age died from COPD, compared
with 122 men and 64 women in 1980. Similarly, 46 men and
44 women died from asthma in 1991, compared with 94
men and 97 women in 1980. Mortality rates for COPD and
asthma in men and women between 1956 to 1994 are shown
in Fig. 5.
The expected lost life-years, i.e. the dierence between
the expected lifetime (36) and the age at death, were
estimated for COPD and asthma (Fig. 6). The number of
life-years lost because of COPD has increased consistently
between 1960–1962 and 1990–1992. By contrast, the
number of life-years lost because of asthma has tended to
decline during the same period, although there appears to
have been a marked increase between 1975–1977 and
1980–1982.
FIG. 2. Hospital discharges for asthma and COPD per 100 000 inhabitants between 1977 and 1991 (1984 data missing).
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METHODOLOGY
Cost-of illness studies typically present ex-post information
on the economic impact of diseases for some year(s) in the
past, the result being dependent on the prevalence of
disease, the medical technology used, the incentives (and
disincentives) to patients and doctors created by the way
healthcare and insurance against healthcare costs and
income losses are organized, etc. Cost-of-illness studies do
not, however, provide any information about how re-
sources should have been used, nor about the ex-ante issues
of how scarce healthcare resources should be used in the
future (2). Therefore, cost-of-illness studies should not be
mistakenly mixed with such normative economic evaluation
techniques as cost-benefit, cost-utility, or cost-eectiveness
analysis (37).FIG. 3. Hospital discharges for COPD per 100 000 inhabitants inSingle year estimates of the total cost of a disease have
been criticized in the literature, and rightly so, for
producing information of rather limited value (38,39). In
order to be meaningful, comparisons have to be made,
either as the development of cost over time (both in
absolute terms and as percentages of aggregates such as the
total cost of illness) or as international comparisons across
countries (which could be for a single year or for a series of
years). Moreover, costs should never be presented as totals
only but disaggregated into their separate components and
with information not only in monetary but also in physical
terms (2).
For comparisons to be valid and reliable, they must be
based on a commonly used methodology and on good data
suitable for the purpose. Although the theoretical principles
of cost-of-illness studies are fairly well accepted, the
empirical applications vary (1,2,40). Studies may dier in
several respects—basic assumptions, cost components1980 (&) and 1991 (&), according to age.
FIG. 4. Hospital discharges for asthma per 100 000 inhabitants in 1980 (&) and 1991 (&), according to age.
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which too often makes direct comparisons among studies
dicult or even impossible.
COPD and asthma are two closely related diseases that
are sometimes hard to distinguish, often occur at the same
time (at least in older patients), and may be mutually
causative. Furthermore, the practice of diagnosis also
diers among countries (41), making comparisons of the
costs associated with these diseases dicult. An important
aspect of this study is that the direct and indirect costs of
the two diseases were estimated simultaneously for 1980
and 1991, which made it possible to analyse dierences in
costs associated with the two diseases as well as trends
occurring over time. Direct comparisons with aggregated
costs for all diseases and for diseases of the respiratory
system in Sweden 1980 and 1991 were facilitated by the fact
that exactly the same methodology and data set had beenFIG. 5. Mortality from asthma and COPD per 100 000 inhabitaused in another study by the present authors (3).
Dierences in methodology etc. made us refrain from
making direct comparisons with the results of studies from
other countries.
DIFFERENCES IN COSTS ASSOCIATED
WITH ASTHMA AND COPD
The total economic costs of COPD and asthma are almost
identical, but the relative contribution of the dierent
components varies between the two diseases. The 1991 data
show that drug costs are lower for COPD than for asthma.
The main reasons for this are that asthma is more amenable
to pharmacological treatment, and that new and relatively
expensive drugs have been introduced during the 1980s. It is
also important to recognize that patterns of asthmants between 1956 and 1994.
FIG. 6. Life-years lost due to premature death from COPD or asthma.
ECONOMIC IMPACT OF ASTHMA AND COPD IN SWEDEN 253treatment have changed during the period covered by this
study due to the increased understanding of the underlying
disease mechanism.
The costs of inpatient care were nearly 70% higher for
COPD than for asthma, but there were more hospital
discharges for asthma than for COPD (19 000 and 16 000,
respectively, in 1991). Moreover, the daily cost of inpatient
care tended to be more expensive for asthma than for
COPD, because only 38% of asthma bed-days were in long-
term care, the daily cost of which is about three quarters of
that of a pulmonary department in a general hospital; by
contrast, 44% of bed-days for COPD were in long-term
care. Similarly, 8% of asthma bed-days were in paediatric
departments, where the cost of treatment was 18 times
higher than in a pulmonary department. Hence, the higher
cost of inpatient treatment for COPD reflects the longer
duration of hospitalization, compared with that for asthma.
One reason for this is that COPD inpatients were
substantially older than asthma inpatients and older
patients are usually hospitalized for longer than younger
patients.
The costs associated with temporary morbidity were
higher for COPD than for asthma. This dierence may be
due to a higher prevalence of COPD, to a longer duration
and/or higher frequency of sick leave due to COPD for
individuals between 16 and 65 years old; however, the small
sample and the uncertainty surrounding the diagnosis-
related sick leave have to be kept in mind.
The indirect cost of permanent disability for asthma was
about SEK 300 million higher than the corresponding cost
for COPD. In 1990–1992 there were 150 more early
retirement pensions, expressed as full time equivalents,
granted for asthma than for COPD. The average age of
early retirement was lower for persons with asthma than for
persons with COPD, and hence the costs of permanent
disability were higher. Among women, more early retire-
ments were granted for asthma than for COPD; this tended
to reduce the relative cost dierence between asthma andCOPD because women’s earnings are generally lower than
men’s.
Mortality from COPD in 1991 was nearly four times
higher than asthma mortality but, because the estimated
cost of mortality includes only individuals who died before
the age of 65 (155 for COPD and 90 for asthma respectively
in 1990–1992), this marked dierence in mortality is not
reflected in the indirect cost. People dying early from
COPD tended to be closer to 65 years of age than those
dying from asthma (mean age at death 58 and 50 years,
respectively), and hence the costs attributable to asthma
deaths were relatively high compared to those associated
with COPD. Thus, in total, the indirect cost of mortality
was only somewhat lower for asthma than for COPD in
1991.
TRENDS IN COSTS BETWEEN 1980 AND
1991
In addition to dierences in the relative distribution of the
cost components, asthma and COPD showed diering
trends for each component between 1980 and 1991 (Fig. 1).
All direct costs associated with COPD increased between
1980 and 1991; the increased cost of inpatient care was due
to an increased number of discharges (Fig. 2). By contrast,
the cost of inpatient care for asthma decreased, while the
cost of outpatient care, GP visits and drugs increased
substantially. These changes were principally due to an
increase in prevalence and to the introduction of new drugs,
primarily inhaled corticosteroids, during the 1980s, which
seems to have decreased the need for inpatient care (19). In
addition to reducing the cost of inpatient care, this would
also be expected to reduce intangible costs as a reduction in
the number of hospitalizations should improve quality of
life.
The indirect cost of permanent disability remained
almost constant, although the cost associated with asthma
254 L. JACOBSON ET AL.increased slightly, while that associated with COPD
decreased slightly. This relative stability is remarkable in
view of the increase in prevalence of both diseases, and
because the general number of newly granted early
retirement pensions for all diagnoses increased by 24%
(full time equivalents) between 1980 and 1992. The increase
in pensions granted to women, and the decrease in those
granted to men, further decreased the cost of permanent
disability due to COPD, since women tend to earn less than
men. The mean ages at early retirement were not changed
for either of the diseases, being 56 and 57 years for men and
women, respectively, for asthma, and 58 and 59 years,
respectively, for COPD in both 1980 and 1991.
While the indirect cost of mortality for asthma was
almost halved, the cost of COPD remained almost
constant. Because this trend in the indirect costs from
mortality does not reflect the trend in the total number of
deaths during the period, but only changes in mortality
among individuals dying before the age of 65, the number
of lost life-years for all age groups was also estimated
(Table 2). For asthma the number of deaths and number of
lost life-years decreased by 20% and 32% respectively,
while for COPD, the number of deaths and number of lost
life-years increased by 31% and 28% respectively between
1980–1982 and 1990–1992; thus indicating that the average
age at death from both diseases increased.
The importance of smoking as a risk factor for COPD
was not appreciated until the 1950s. In Sweden, women
began to smoke substantially more after the Second World
War, and this fact seems to be reflected in the mortality
data (Fig. 4). The increase in mortality among males took
place already in the 1960s and 1970s, whereas the increase
in female mortality occurred in the late 1980s.
Conclusion
In conclusion, this study has highlighted the economic
impact of asthma and COPD in Sweden. The two
conditions together account for about 2% of total disease
costs, and 26% of costs associated with respiratory
diseases. Moreover, the study has identified a number of
important trends in the use of healthcare resources. Since
1980, expenditure on drugs and outpatient care for asthma
has increased to a greater extent than the corresponding
costs for COPD. Conversely, the costs associated
with inpatient care for asthma have decreased by about
a third, whereas inpatient costs for COPD have increased
by about a half. These changes largely reflect the recogni-
tion that asthma is an inflammatory disease and the
corresponding changes in prescribing habits. Today, the
challenge is for a similar break-through in the treatment
of COPD.
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